Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2021-06-29 00:46:36 UTC |
---|
NP-MRD ID | NP0001203 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Taurodeoxycholic acid |
---|
Description | Taurodeoxycholic acid is a bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.G. Membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487 , 16037564 , 12576301 , 11907135 ). Taurodeoxycholic acid can be found in Escherichia (PMID: 30736766 ). |
---|
Structure | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O InChI=1S/C26H45NO6S/c1-16(4-9-24(30)27-12-13-34(31,32)33)20-7-8-21-19-6-5-17-14-18(28)10-11-25(17,2)22(19)15-23(29)26(20,21)3/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17-,18-,19+,20-,21+,22+,23+,25+,26-/m1/s1 |
---|
Synonyms | Value | Source |
---|
Taurodeoxycholate | ChEBI | Acid, taurodeoxycholic | HMDB | Deoxycholate, taurine | HMDB | Sodium taurodeoxycholate | HMDB | Taurine deoxycholate | HMDB | Deoxycholyltaurine | HMDB | Taurodeoxycholate, sodium | HMDB | Deoxytaurocholate | HMDB | Deoxytaurocholic acid | HMDB | N-(3a,12a-Dihydroxy-5b-cholan-24-oyl)-taurine | HMDB | Sodium taurodeoxylate | HMDB | Taurodeoxycholic acid sodium salt | HMDB | Taurodeoxycholic acid sodium salt hydrate | HMDB | Taurodesoxycholate | HMDB | Taurodesoxycholic acid | HMDB | Tudcabil | HMDB |
|
---|
Chemical Formula | C26H45NO6S |
---|
Average Mass | 499.7040 Da |
---|
Monoisotopic Mass | 499.29676 Da |
---|
IUPAC Name | 2-[(4R)-4-[(1S,2S,5R,7R,10R,11S,14R,15R,16S)-5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid |
---|
Traditional Name | 2-[(4R)-4-[(1S,2S,5R,7R,10R,11S,14R,15R,16S)-5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethanesulfonic acid |
---|
CAS Registry Number | 516-50-7 |
---|
SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O |
---|
InChI Identifier | InChI=1S/C26H45NO6S/c1-16(4-9-24(30)27-12-13-34(31,32)33)20-7-8-21-19-6-5-17-14-18(28)10-11-25(17,2)22(19)15-23(29)26(20,21)3/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17-,18-,19+,20-,21+,22+,23+,25+,26-/m1/s1 |
---|
InChI Key | AWDRATDZQPNJFN-VAYUFCLWSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as taurinated bile acids and derivatives. These are bile acid derivatives containing a taurine conjugated to the bile acid moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Bile acids, alcohols and derivatives |
---|
Direct Parent | Taurinated bile acids and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Taurinated bile acid
- Dihydroxy bile acid, alcohol, or derivatives
- Hydroxy bile acid, alcohol, or derivatives
- 3-hydroxysteroid
- 12-hydroxysteroid
- 3-alpha-hydroxysteroid
- Hydroxysteroid
- Fatty amide
- Fatty acyl
- N-acyl-amine
- Cyclic alcohol
- Alkanesulfonic acid
- Sulfonyl
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Organosulfonic acid
- Secondary alcohol
- Secondary carboxylic acid amide
- Carboxamide group
- Carboxylic acid derivative
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Alcohol
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organosulfur compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 204 - 208 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 41 mg/mL | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Foley DP, Collins BR, Magee JC, Platt JL, Katz E, Harland RC, Meyers WC, Chari RS: Bile acids in xenogeneic ex-vivo liver perfusion: function of xenoperfused livers and compatibility with human bile salts and porcine livers. Transplantation. 2000 Jan 27;69(2):242-8. [PubMed:10670634 ]
- Bretagne JF, Vidon N, L'Hirondel C, Bernier JJ: Increased cell loss in the human jejunum induced by laxatives (ricinoleic acid, dioctyl sodium sulphosuccinate, magnesium sulphate, bile salts). Gut. 1981 Apr;22(4):264-9. [PubMed:6165655 ]
- Leveau P, Wang X, Sun Z, Borjesson A, Andersson E, Andersson R: Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant. Biochem Pharmacol. 2005 May 1;69(9):1325-31. [PubMed:15826603 ]
- Lim HJ, Kim SY, Lee WK: Isolation of cholesterol-lowering lactic acid bacteria from human intestine for probiotic use. J Vet Sci. 2004 Dec;5(4):391-5. [PubMed:15613825 ]
- Muhlbauer M, Allard B, Bosserhoff AK, Kiessling S, Herfarth H, Rogler G, Scholmerich J, Jobin C, Hellerbrand C: Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G1000-8. Epub 2004 Jan 15. [PubMed:14726307 ]
- Elkins CA, Mullis LB: Bile-mediated aminoglycoside sensitivity in Lactobacillus species likely results from increased membrane permeability attributable to cholic acid. Appl Environ Microbiol. 2004 Dec;70(12):7200-9. [PubMed:15574918 ]
- Aubert E, Sbarra V, Le Petit-Thevenin J, Valette A, Lombardo D: Site-directed mutagenesis of the basic N-terminal cluster of pancreatic bile salt-dependent lipase. Functional significance. J Biol Chem. 2002 Sep 20;277(38):34987-96. Epub 2002 Jul 10. [PubMed:12110666 ]
- Xie Q, Li GM, Zhou XQ, Liao D, Yu H, Guo Q: [Effect of Tauroursodeoxycholic acid on cytochrome C-mediated apoptosis in HepG2 cells]. Zhonghua Gan Zang Bing Za Zhi. 2003 May;11(5):298-301. [PubMed:12773247 ]
|
---|